pharma · Pancreatic Ductal Adenocarcinoma · Neuroendocrine Tumor Grade 2 · CATX
Perspective Therapeutics
Perspective Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2023
- Employees
- 144
- Programs
- 6
- Drugs
- 1
- Patents
- 1
Perspective Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Perspective Therapeutics.
Perspective Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
[203Pb]Pb-PSV359
Perspective Therapeutics
Pancreatic Ductal Adenocarcinoma
1 trial -
[203Pb]VMT-α-NET
Perspective Therapeutics
Neuroendocrine Tumors Unresectable
1 trial -
[203Pb]VMT01
Perspective Therapeutics
Recurrent Melanoma (Skin)
1 trial -
[203Pb]VMT-α-NET
Perspective Therapeutics
Neuroendocrine Tumor Grade 2
1 trial -
[203Pb]VMT01
Perspective Therapeutics
Melanoma (Skin)
1 trial -
[212Pb] VMT-α-NET
Perspective Therapeutics
Neuroendocrine Tumors
1 trial
Frequently asked questions
How many clinical projects does Perspective Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.